Low-dose UVA1 Radiation in Cutaneous Lupus Patients
| Status: | Recruiting |
|---|---|
| Conditions: | Lupus |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/18/2018 |
| Start Date: | September 2012 |
| End Date: | September 2022 |
| Contact: | Benjamin F Chong, MD, MSCS |
| Email: | skinlupus.registry@utsouthwestern.edu |
| Phone: | 214-648-3427 |
The investigators are conducting an open-label clinical trial determining the effects of UVA1
phototherapy on cutaneous lupus (CLE) patients. Past research on systemic lupus (SLE)
subjects indicates that this treatment is likely to be effective in treating cutaneous lupus
with few side effects. The fact that most CLE patients are seen at dermatology clinics also
increases the usefulness of this study because there is a large probability that phototherapy
treatment will be accessible for many of the patients that stand to benefit from it.
phototherapy on cutaneous lupus (CLE) patients. Past research on systemic lupus (SLE)
subjects indicates that this treatment is likely to be effective in treating cutaneous lupus
with few side effects. The fact that most CLE patients are seen at dermatology clinics also
increases the usefulness of this study because there is a large probability that phototherapy
treatment will be accessible for many of the patients that stand to benefit from it.
Study subjects will receive low dose (20 J/cm2) UVA1 phototherapy treatment three times per
week for 10 weeks. Each treatment will take less than 30 minutes. This period will be
followed by an eight-week observation phase to assess longer term effects of the treatment.
Patients will be assessed for disease activity, and blood studies and photos will be
completed prior to, during, and after phototherapy treatment. Optional skin biopsies of
affected and unaffected skin will be performed at the beginning and end of the active
treatment phase.
week for 10 weeks. Each treatment will take less than 30 minutes. This period will be
followed by an eight-week observation phase to assess longer term effects of the treatment.
Patients will be assessed for disease activity, and blood studies and photos will be
completed prior to, during, and after phototherapy treatment. Optional skin biopsies of
affected and unaffected skin will be performed at the beginning and end of the active
treatment phase.
Inclusion Criteria:
- You must be 18 years or older with a diagnosis of cutaneous lupus.
- You must have at least two active areas of cutaneous lupus.
- You will need to come in three days a week for a 10-week period.
- You will need to participate in four physician visits and blood draws.
Exclusion Criteria:
- You do not have a diagnosis of cutaneous lupus.
- You have less than two active areas of cutaneous lupus.
- You are unable to come in three days a week for treatment for a 10-week period.
We found this trial at
1
site
1801 Inwood Rd
Dallas, Texas 75390
Dallas, Texas 75390
(214) 645-3300
Phone: 214-648-3427
University of Texas Southwestern Medical Center UT Southwestern is an academic medical center, world-renowned for...
Click here to add this to my saved trials
